Publication:
Exendin-4 as a versatile therapeutic agent for the amelioration of diabetic changes

Simple item page
dc.contributor.coauthorAhmadi, Mahdi
dc.contributor.coauthorAslani, Somayeh
dc.contributor.coauthorSaberianpour, Shirin
dc.contributor.coauthorRahbarghazi, Reza
dc.contributor.departmentKUTTAM (Koç University Research Center for Translational Medicine)
dc.contributor.departmentGraduate School of Health Sciences
dc.contributor.kuauthorRajabi, Hadi
dc.contributor.kuprofileFaculty Member
dc.contributor.schoolcollegeinstituteGRADUATE SCHOOL OF HEALTH SCIENCES
dc.contributor.schoolcollegeinstituteResearch Center
dc.date.accessioned2024-11-09T12:12:19Z
dc.date.issued2022
dc.description.abstractType 2 diabetes mellitus (T2DM) is a chronic metabolic abnormality leading to microvascular and macrovascular complications. Non-insulin Incretin mimic synthetic peptide exendin-4 was introduced as an anti-diabetic drug which helped diabetic patients with triggering insulin secretion; further researches have revealed an effective role of exendin-4 in treatment of T2DM related diseases. Exendin-4 is approximately similar to Glucagon like peptide, thus it can bind to the glucagon-like peptide-1 receptor (GLP-1R) and activated different signaling pathways that are involved in various bioactivides such as apoptosis, insulin secretion and inactivation of microglial. In this review, we investigated the interesting role of exendin-4 in various kinds of T2DM related disorders through the activation of different signaling pathways.
dc.description.fulltextYES
dc.description.indexedbyWoS
dc.description.indexedbyScopus
dc.description.indexedbyPubMed
dc.description.issue2
dc.description.openaccessYES
dc.description.publisherscopeInternational
dc.description.sponsoredbyTubitakEuN/A
dc.description.sponsorshipN/A
dc.description.versionPublisher version
dc.description.volume12
dc.formatpdf
dc.identifier.doi10.34172/apb.2022.025
dc.identifier.eissn2251-7308
dc.identifier.embargoNO
dc.identifier.filenameinventorynoIR03520
dc.identifier.issn2228-5881
dc.identifier.linkhttps://doi.org/10.34172/apb.2022.025
dc.identifier.quartileN/A
dc.identifier.scopus2-s2.0-85128166956
dc.identifier.urihttps://hdl.handle.net/20.500.14288/1154
dc.identifier.wos768125100004
dc.keywordsDiabetes complications
dc.keywordsExendin-4
dc.keywordsSignaling pathways
dc.languageEnglish
dc.publisherTabriz University of Medical Sciences
dc.relation.grantnoNA
dc.relation.urihttp://cdm21054.contentdm.oclc.org/cdm/ref/collection/IR/id/10315
dc.sourceAdvanced Pharmaceutical Bulletin
dc.subjectPharmacology and pharmacy
dc.titleExendin-4 as a versatile therapeutic agent for the amelioration of diabetic changes
dc.typeReview
dspace.entity.typePublication
local.contributor.kuauthorRajabi, Hadi
local.publication.orgunit1GRADUATE SCHOOL OF HEALTH SCIENCES
local.publication.orgunit1Research Center
local.publication.orgunit2KUTTAM (Koç University Research Center for Translational Medicine)
local.publication.orgunit2Graduate School of Health Sciences
relation.isOrgUnitOfPublication91bbe15d-017f-446b-b102-ce755523d939
relation.isOrgUnitOfPublication2f870f28-12c9-4b28-9465-b91a69c1d48c
relation.isOrgUnitOfPublication.latestForDiscovery91bbe15d-017f-446b-b102-ce755523d939
relation.isParentOrgUnitOfPublication4c75e0a5-ca7f-4443-bd78-1b473d4f6743
relation.isParentOrgUnitOfPublicationd437580f-9309-4ecb-864a-4af58309d287
relation.isParentOrgUnitOfPublication.latestForDiscovery4c75e0a5-ca7f-4443-bd78-1b473d4f6743

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
10315.pdf
Size:
972.04 KB
Format:
Adobe Portable Document Format
Download

Collections

Publications with Fulltext